Cargando…

VHL-recruiting PROTAC attenuates renal fibrosis and preserves renal function via simultaneous degradation of Smad3 and stabilization of HIF-2α

BACKGROUND: Renal fibrosis is the pathological foundation of various chronic kidney diseases progressing to end stage renal failure. However, there are currently no nephroprotective drugs targeted to the fibrotic process in clinical practice. Proteolytic targeting chimeras (PROTACs), which reversibl...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jiayi, Ruan, Yuyi, Wang, Dan, Fan, Jinjin, Luo, Ning, Chen, Huiting, Li, Xiaoyan, Chen, Wei, Wang, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761961/
https://www.ncbi.nlm.nih.gov/pubmed/36536448
http://dx.doi.org/10.1186/s13578-022-00936-x
_version_ 1784852774362546176
author Yang, Jiayi
Ruan, Yuyi
Wang, Dan
Fan, Jinjin
Luo, Ning
Chen, Huiting
Li, Xiaoyan
Chen, Wei
Wang, Xin
author_facet Yang, Jiayi
Ruan, Yuyi
Wang, Dan
Fan, Jinjin
Luo, Ning
Chen, Huiting
Li, Xiaoyan
Chen, Wei
Wang, Xin
author_sort Yang, Jiayi
collection PubMed
description BACKGROUND: Renal fibrosis is the pathological foundation of various chronic kidney diseases progressing to end stage renal failure. However, there are currently no nephroprotective drugs targeted to the fibrotic process in clinical practice. Proteolytic targeting chimeras (PROTACs), which reversibly degrade target proteins through the ubiquitin–proteasome pathway, is a novel therapeutic modality. Smad3 is a key pathogenic factor in fibrogenesis while HIF-2α exhibits prominent renal protective effects, which is the natural substrate of von Hippel–Lindau (VHL) E3 Ligase. We hypothesied the construction of VHL-recruiting, Smad3-targeting PROTAC might combine the effects of Smad3 degradation and HIF-2α stabilization, which not only improving the clinical efficacy of PROTAC but also avoiding its potential off-target effects, could greatly improve the possibility of its translation into clinical drugs. METHODS: By joining the Smad3-binding small molecule compound (SMC) to VHL-binding SMC with a linker, we designed and synthesized a Smad3-targeting, VHL-based PROTAC. The effects of this PROTAC on targeted proteins were verified both in vitro and in vivo. The toxicity and pharmacokinetic (PK) evaluations were conducted with both male and female mice. The renal protection effects and mechanism of PROTAC were evaluated in unilateral ureteral obstruction (UUO) and 5/6 subtotal nephrectomy (5/6Nx) mouse model. RESULTS: By optimizing the linker and the Smad3-binding SMC, we got a stable and high efficient PROTAC which simultaneously degraded Smad3 and stabilized HIF-2α both in vivo and in vitro. The acute toxicity evaluation showed a pretty large therapeutic window of the PROTAC. The prominent renal protection effects and its underlying mechanism including anti-fibrosis and anti-inflammatory, improving renal anemia and promoting kidney repair, had all been verified in UUO and 5/6Nx mouse model. CONCLUSION: By accurate combination of PROTAC targeted protein and E3 ligase, we got a Smad3-targeting, VHL-recruting PROTAC which caused Smad3 degradation and HIF-2α stabilization effects simultaneously, and led to the strong renal function protection effects. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13578-022-00936-x.
format Online
Article
Text
id pubmed-9761961
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97619612022-12-20 VHL-recruiting PROTAC attenuates renal fibrosis and preserves renal function via simultaneous degradation of Smad3 and stabilization of HIF-2α Yang, Jiayi Ruan, Yuyi Wang, Dan Fan, Jinjin Luo, Ning Chen, Huiting Li, Xiaoyan Chen, Wei Wang, Xin Cell Biosci Research BACKGROUND: Renal fibrosis is the pathological foundation of various chronic kidney diseases progressing to end stage renal failure. However, there are currently no nephroprotective drugs targeted to the fibrotic process in clinical practice. Proteolytic targeting chimeras (PROTACs), which reversibly degrade target proteins through the ubiquitin–proteasome pathway, is a novel therapeutic modality. Smad3 is a key pathogenic factor in fibrogenesis while HIF-2α exhibits prominent renal protective effects, which is the natural substrate of von Hippel–Lindau (VHL) E3 Ligase. We hypothesied the construction of VHL-recruiting, Smad3-targeting PROTAC might combine the effects of Smad3 degradation and HIF-2α stabilization, which not only improving the clinical efficacy of PROTAC but also avoiding its potential off-target effects, could greatly improve the possibility of its translation into clinical drugs. METHODS: By joining the Smad3-binding small molecule compound (SMC) to VHL-binding SMC with a linker, we designed and synthesized a Smad3-targeting, VHL-based PROTAC. The effects of this PROTAC on targeted proteins were verified both in vitro and in vivo. The toxicity and pharmacokinetic (PK) evaluations were conducted with both male and female mice. The renal protection effects and mechanism of PROTAC were evaluated in unilateral ureteral obstruction (UUO) and 5/6 subtotal nephrectomy (5/6Nx) mouse model. RESULTS: By optimizing the linker and the Smad3-binding SMC, we got a stable and high efficient PROTAC which simultaneously degraded Smad3 and stabilized HIF-2α both in vivo and in vitro. The acute toxicity evaluation showed a pretty large therapeutic window of the PROTAC. The prominent renal protection effects and its underlying mechanism including anti-fibrosis and anti-inflammatory, improving renal anemia and promoting kidney repair, had all been verified in UUO and 5/6Nx mouse model. CONCLUSION: By accurate combination of PROTAC targeted protein and E3 ligase, we got a Smad3-targeting, VHL-recruting PROTAC which caused Smad3 degradation and HIF-2α stabilization effects simultaneously, and led to the strong renal function protection effects. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13578-022-00936-x. BioMed Central 2022-12-19 /pmc/articles/PMC9761961/ /pubmed/36536448 http://dx.doi.org/10.1186/s13578-022-00936-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yang, Jiayi
Ruan, Yuyi
Wang, Dan
Fan, Jinjin
Luo, Ning
Chen, Huiting
Li, Xiaoyan
Chen, Wei
Wang, Xin
VHL-recruiting PROTAC attenuates renal fibrosis and preserves renal function via simultaneous degradation of Smad3 and stabilization of HIF-2α
title VHL-recruiting PROTAC attenuates renal fibrosis and preserves renal function via simultaneous degradation of Smad3 and stabilization of HIF-2α
title_full VHL-recruiting PROTAC attenuates renal fibrosis and preserves renal function via simultaneous degradation of Smad3 and stabilization of HIF-2α
title_fullStr VHL-recruiting PROTAC attenuates renal fibrosis and preserves renal function via simultaneous degradation of Smad3 and stabilization of HIF-2α
title_full_unstemmed VHL-recruiting PROTAC attenuates renal fibrosis and preserves renal function via simultaneous degradation of Smad3 and stabilization of HIF-2α
title_short VHL-recruiting PROTAC attenuates renal fibrosis and preserves renal function via simultaneous degradation of Smad3 and stabilization of HIF-2α
title_sort vhl-recruiting protac attenuates renal fibrosis and preserves renal function via simultaneous degradation of smad3 and stabilization of hif-2α
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761961/
https://www.ncbi.nlm.nih.gov/pubmed/36536448
http://dx.doi.org/10.1186/s13578-022-00936-x
work_keys_str_mv AT yangjiayi vhlrecruitingprotacattenuatesrenalfibrosisandpreservesrenalfunctionviasimultaneousdegradationofsmad3andstabilizationofhif2a
AT ruanyuyi vhlrecruitingprotacattenuatesrenalfibrosisandpreservesrenalfunctionviasimultaneousdegradationofsmad3andstabilizationofhif2a
AT wangdan vhlrecruitingprotacattenuatesrenalfibrosisandpreservesrenalfunctionviasimultaneousdegradationofsmad3andstabilizationofhif2a
AT fanjinjin vhlrecruitingprotacattenuatesrenalfibrosisandpreservesrenalfunctionviasimultaneousdegradationofsmad3andstabilizationofhif2a
AT luoning vhlrecruitingprotacattenuatesrenalfibrosisandpreservesrenalfunctionviasimultaneousdegradationofsmad3andstabilizationofhif2a
AT chenhuiting vhlrecruitingprotacattenuatesrenalfibrosisandpreservesrenalfunctionviasimultaneousdegradationofsmad3andstabilizationofhif2a
AT lixiaoyan vhlrecruitingprotacattenuatesrenalfibrosisandpreservesrenalfunctionviasimultaneousdegradationofsmad3andstabilizationofhif2a
AT chenwei vhlrecruitingprotacattenuatesrenalfibrosisandpreservesrenalfunctionviasimultaneousdegradationofsmad3andstabilizationofhif2a
AT wangxin vhlrecruitingprotacattenuatesrenalfibrosisandpreservesrenalfunctionviasimultaneousdegradationofsmad3andstabilizationofhif2a